No Cover Image

Journal article 534 views 104 downloads

Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review

Kevin Fernando, Steve Bain Orcid Logo, Patrick Holmes, Philip Newland Jones, Dipesh C. Patel

Diabetes Therapy, Volume: 12, Issue: 9, Pages: 2267 - 2288

Swansea University Author: Steve Bain Orcid Logo

  • 58128.pdf

    PDF | Version of Record

    ©The Author(s) 2021. This article is licensed under a Creative Commons Attribution NonCommercial 4.0 International License

    Download (2.6MB)

Check full text

DOI (Published version): 10.1007/s13300-021-01116-9

Abstract

The scientific landscape of treatments for type 2 diabetes (T2D) has changed rapidly in the last decade with newer treatments becoming available. However, a large proportion of people with T2D are not able to achieve glycaemic goals because of clinical inertia. The majority of T2D management is in p...

Full description

Published in: Diabetes Therapy
ISSN: 1869-6953 1869-6961
Published: Springer Science and Business Media LLC 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa58128
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2021-09-28T12:43:58Z
last_indexed 2023-01-11T14:38:30Z
id cronfa58128
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-12-02T18:42:57.2064736</datestamp><bib-version>v2</bib-version><id>58128</id><entry>2021-09-28</entry><title>Glucagon-Like Peptide&#xA0;1 Receptor Agonist Usage in Type&#xA0;2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-09-28</date><deptcode>BMS</deptcode><abstract>The scientific landscape of treatments for type 2 diabetes (T2D) has changed rapidly in the last decade with newer treatments becoming available. However, a large proportion of people with T2D are not able to achieve glycaemic goals because of clinical inertia. The majority of T2D management is in primary care, where clinicians (medical, nursing and pharmacist staff) play an important role in addressing patient needs and achieving treatment goals. However, management of T2D is challenging because of the heterogeneity of T2D and complexity of comorbidity, time constraints, guidance overload and the evolving treatments. Additionally, the current coronavirus disease pandemic poses additional challenges to the management of chronic diseases such as T2D, including routine access to patients for monitoring and communication. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of agents that have evolved rapidly in recent years. These agents act in a glucose-dependent manner to promote insulin secretion and inhibit glucagon secretion, as well as enhancing satiety and reducing hunger. As a result, they are effective treatment options for people with T2D, achieving glycated haemoglobin reductions, weight loss and potential cardiovascular benefit, as monotherapy or as add-on to other glucose-lowering therapies. However, given the complexity of managing T2D, it is important to equip primary care clinicians with clear information regarding efficacy, safety and appropriate positioning of GLP-1 RA therapies in clinical practice. This review provides a summary of clinical and real-world evidence along with practical guidance, with the aim of aiding primary care clinicians in the initiation and monitoring of GLP-1 RAs to help ensure that desired outcomes are realised. Furthermore, a benefit/risk tool has been developed on the basis of current available evidence and guidelines to support primary care clinicians in selecting individuals who are most likely to benefit from GLP-1 RA therapies, in addition to indicating clinical situations where caution is needed.</abstract><type>Journal Article</type><journal>Diabetes Therapy</journal><volume>12</volume><journalNumber>9</journalNumber><paginationStart>2267</paginationStart><paginationEnd>2288</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1869-6953</issnPrint><issnElectronic>1869-6961</issnElectronic><keywords>Clinical guidance; Glucagon-like peptide 1 receptor agonist; Glucose-lowering medicines; Prescribing tools; Primary care; Risk/benefit; Therapy choice; Type 2 diabetes</keywords><publishedDay>1</publishedDay><publishedMonth>9</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-09-01</publishedDate><doi>10.1007/s13300-021-01116-9</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>Novo Nordisk Inc.</funders><projectreference/><lastEdited>2022-12-02T18:42:57.2064736</lastEdited><Created>2021-09-28T13:41:05.5699610</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Kevin</firstname><surname>Fernando</surname><order>1</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>2</order></author><author><firstname>Patrick</firstname><surname>Holmes</surname><order>3</order></author><author><firstname>Philip Newland</firstname><surname>Jones</surname><order>4</order></author><author><firstname>Dipesh C.</firstname><surname>Patel</surname><order>5</order></author></authors><documents><document><filename>58128__21288__42d044bd37dd421f88655bc2b959058e.pdf</filename><originalFilename>58128.pdf</originalFilename><uploaded>2021-10-25T12:41:14.6666976</uploaded><type>Output</type><contentLength>2724810</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9;The Author(s) 2021. This article is licensed under a Creative Commons Attribution NonCommercial 4.0 International License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-12-02T18:42:57.2064736 v2 58128 2021-09-28 Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2021-09-28 BMS The scientific landscape of treatments for type 2 diabetes (T2D) has changed rapidly in the last decade with newer treatments becoming available. However, a large proportion of people with T2D are not able to achieve glycaemic goals because of clinical inertia. The majority of T2D management is in primary care, where clinicians (medical, nursing and pharmacist staff) play an important role in addressing patient needs and achieving treatment goals. However, management of T2D is challenging because of the heterogeneity of T2D and complexity of comorbidity, time constraints, guidance overload and the evolving treatments. Additionally, the current coronavirus disease pandemic poses additional challenges to the management of chronic diseases such as T2D, including routine access to patients for monitoring and communication. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of agents that have evolved rapidly in recent years. These agents act in a glucose-dependent manner to promote insulin secretion and inhibit glucagon secretion, as well as enhancing satiety and reducing hunger. As a result, they are effective treatment options for people with T2D, achieving glycated haemoglobin reductions, weight loss and potential cardiovascular benefit, as monotherapy or as add-on to other glucose-lowering therapies. However, given the complexity of managing T2D, it is important to equip primary care clinicians with clear information regarding efficacy, safety and appropriate positioning of GLP-1 RA therapies in clinical practice. This review provides a summary of clinical and real-world evidence along with practical guidance, with the aim of aiding primary care clinicians in the initiation and monitoring of GLP-1 RAs to help ensure that desired outcomes are realised. Furthermore, a benefit/risk tool has been developed on the basis of current available evidence and guidelines to support primary care clinicians in selecting individuals who are most likely to benefit from GLP-1 RA therapies, in addition to indicating clinical situations where caution is needed. Journal Article Diabetes Therapy 12 9 2267 2288 Springer Science and Business Media LLC 1869-6953 1869-6961 Clinical guidance; Glucagon-like peptide 1 receptor agonist; Glucose-lowering medicines; Prescribing tools; Primary care; Risk/benefit; Therapy choice; Type 2 diabetes 1 9 2021 2021-09-01 10.1007/s13300-021-01116-9 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University Novo Nordisk Inc. 2022-12-02T18:42:57.2064736 2021-09-28T13:41:05.5699610 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Kevin Fernando 1 Steve Bain 0000-0001-8519-4964 2 Patrick Holmes 3 Philip Newland Jones 4 Dipesh C. Patel 5 58128__21288__42d044bd37dd421f88655bc2b959058e.pdf 58128.pdf 2021-10-25T12:41:14.6666976 Output 2724810 application/pdf Version of Record true ©The Author(s) 2021. This article is licensed under a Creative Commons Attribution NonCommercial 4.0 International License true eng http://creativecommons.org/licenses/by-nc/4.0/
title Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
spellingShingle Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
Steve Bain
title_short Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
title_full Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
title_fullStr Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
title_full_unstemmed Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
title_sort Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Kevin Fernando
Steve Bain
Patrick Holmes
Philip Newland Jones
Dipesh C. Patel
format Journal article
container_title Diabetes Therapy
container_volume 12
container_issue 9
container_start_page 2267
publishDate 2021
institution Swansea University
issn 1869-6953
1869-6961
doi_str_mv 10.1007/s13300-021-01116-9
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description The scientific landscape of treatments for type 2 diabetes (T2D) has changed rapidly in the last decade with newer treatments becoming available. However, a large proportion of people with T2D are not able to achieve glycaemic goals because of clinical inertia. The majority of T2D management is in primary care, where clinicians (medical, nursing and pharmacist staff) play an important role in addressing patient needs and achieving treatment goals. However, management of T2D is challenging because of the heterogeneity of T2D and complexity of comorbidity, time constraints, guidance overload and the evolving treatments. Additionally, the current coronavirus disease pandemic poses additional challenges to the management of chronic diseases such as T2D, including routine access to patients for monitoring and communication. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of agents that have evolved rapidly in recent years. These agents act in a glucose-dependent manner to promote insulin secretion and inhibit glucagon secretion, as well as enhancing satiety and reducing hunger. As a result, they are effective treatment options for people with T2D, achieving glycated haemoglobin reductions, weight loss and potential cardiovascular benefit, as monotherapy or as add-on to other glucose-lowering therapies. However, given the complexity of managing T2D, it is important to equip primary care clinicians with clear information regarding efficacy, safety and appropriate positioning of GLP-1 RA therapies in clinical practice. This review provides a summary of clinical and real-world evidence along with practical guidance, with the aim of aiding primary care clinicians in the initiation and monitoring of GLP-1 RAs to help ensure that desired outcomes are realised. Furthermore, a benefit/risk tool has been developed on the basis of current available evidence and guidelines to support primary care clinicians in selecting individuals who are most likely to benefit from GLP-1 RA therapies, in addition to indicating clinical situations where caution is needed.
published_date 2021-09-01T04:14:24Z
_version_ 1763753973016166400
score 11.012678

Similar Items